Cargando…
Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment
BACKGROUND: To compare the efficacy of crizotinib, pemetrexed and other chemotherapy regimens as a first-line treatment in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in real world clinical use and to evaluate the +86–571-87,236,876 predictive clinical...
Autores principales: | Zhou, Jianya, Zheng, Jing, Zhang, Xiaochen, Zhao, Jing, Zhu, Yanping, Shen, Qian, Wang, Yuehong, Sun, Ke, Zhang, Zeying, Pan, Zhijie, Shen, Yihong, Zhou, Jianying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5751674/ https://www.ncbi.nlm.nih.gov/pubmed/29298713 http://dx.doi.org/10.1186/s12885-017-3720-8 |
Ejemplares similares
-
Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement
por: Zhou, Jianya, et al.
Publicado: (2015) -
Outcomes of switching from crizotinib to alectinib in patients with advanced non-small cell lung cancer with anaplastic lymphoma kinase fusion
por: Pan, Yingying, et al.
Publicado: (2021) -
Crizotinib versus platinum‐based double‐agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase‐positive lung adenocarcinoma
por: Zhang, Quan, et al.
Publicado: (2015) -
Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of Anaplastic Lymphoma Kinase‒Positive Anaplastic Large Cell Lymphoma
por: Xu, Wendan, et al.
Publicado: (2018) -
Crizotinib in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma in the setting of renal insufficiency: a case report
por: Kothari, Shalin, et al.
Publicado: (2016)